TRW & Co · Competition and consumer law

CCS Merger Procedure Guidelines 2026: What Changed for Deal Filings

Updated 20 October 2026Legal insightSingapore9 min read
Singapore CBD skyscrapers reflected in still water at sunset, illustrating CCS merger guidelines 2026
Photo: Unsplash.

The CCS merger guidelines 2026 took effect on 1 May 2026. They introduce a 25 working day streamlined Phase 1 for clearly unproblematic deals, cap Phase 1 extensions, cut the Phase 2 target to 100 working days and add a Phase 1 Issues Letter. This guide explains how deal teams should reflect those changes in conditions, long-stop dates and remedies planning.

Key pointThe Phase 1 Issues Letter sets a deadline to offer commitments or move to Phase 2, and CCS will rarely extend Phase 2 to evaluate remedies, so buyers with overlaps need a remedies plan before they file, not after.

At a glance

01

In force 1 May 2026

The revised CCS Guidelines on Merger Procedures apply from 1 May 2026, after consultation from 27 October to 17 November 2025.

02

25-day streamlined track

Mergers that clearly raise no competition concerns receive a streamlined Phase 1 completed within 25 working days, which CCS expects to cover most cases.

03

Capped Phase 1

The standard 30 working day Phase 1 can be extended by up to 20 working days in limited circumstances, giving a maximum of 50.

04

Phase 1 Issues Letter

Where CCS suspects a substantial lessening of competition, it sets out concerns and a deadline to offer commitments or file Form M2.

05

Phase 2 shortened

CCS now aims to complete Phase 2 within 100 working days, down from 120, and rarely extends it to evaluate commitments.

Swipe or scroll →

The short answer: what the CCS merger guidelines 2026 change for deal timetables

The CCS merger guidelines 2026 are the revised CCS Guidelines on Merger Procedures, which took effect on 1 May 2026. They do not change the voluntary nature of Singapore's merger regime or the substantive test of whether a merger substantially lessens competition. What they change is time and information: a 25 working day streamlined Phase 1 for clearly unproblematic deals, a cap on Phase 1 extensions, a 100 working day Phase 2 target, and an earlier formal warning when CCS has concerns.

For deal teams, this means three practical adjustments. Long-stop dates can often be tighter for straightforward deals. Complex deals need a commitments strategy ready before the end of Phase 1, because CCS now issues a Phase 1 Issues Letter with a deadline to offer remedies or move to Phase 2. And the quality of the first filing matters more than ever, because the clock only starts when CCS accepts the application as complete.

This article focuses on those procedural changes and how to build them into a transaction timetable. For the wider regime, including what counts as a merger, the indicative thresholds and application fees, see our practice page on merger control in Singapore.

Marina Bay skyline representing deal timetables under the CCS merger guidelines 2026
The revised procedure rewards complete filings and early remedy planning.

What changed on 1 May 2026

CCS consulted on the changes from 27 October to 17 November 2025 and announced the final revisions to its Merger Procedure Guidelines on 27 March 2026. The feedback was described as largely supportive. CCS framed the reforms around three goals: a streamlined track for mergers unlikely to raise concerns, less burden on merger parties and third parties, and earlier clarity on whether a merger is likely to be cleared.

Key procedural changes (from CCS's revised guidelines and practitioner summaries)
IssueBefore 1 May 2026Under the CCS merger guidelines 2026
Phase 1 for simple dealsOne indicative 30 working day periodStreamlined assessment completed within 25 working days, expected to apply to most mergers
Phase 1 extensionOnly in exceptional circumstances, with no stated capUp to 20 additional working days, so up to 50 in total, in limited circumstances
Warning of concernsNo formal Phase 1 issues mechanismPhase 1 Issues Letter setting out key concerns and a deadline to offer commitments or file Form M2
Phase 1 commitments evaluation50 working days, extendable by up to 4050 working days, extendable by up to 20
Phase 2 target120 working days100 working days
Form M1 confidentialityConfidential and non-confidential versions as a matter of courseConfidential version only, with confidential material in square brackets; non-confidential version only if CCS asks

The current guidelines are available from the CCS page on the Competition Act and Guidelines. The indicative thresholds on CCS's mergers and acquisitions page have not changed: competition concerns are generally unlikely unless the merged entity will have a market share of 40% or more, or between 20% and 40% where the three largest firms together hold 70% or more.

Before filing: pre-notification and confidential advice

The revised guidelines continue to encourage pre-notification discussions. CCS expects parties to show a good faith intention to proceed, and generally regards a draft sale and purchase agreement as evidence of that. Discussions are most useful when the parties supply a draft Form M1, so that CCS can point out gaps and parties can explain why some questions are irrelevant to their deal. CCS's guidance on discussing a merger sets out how to request a meeting.

CCS does not, in pre-notification discussions, say whether a deal is likely to need Phase 2 or would lead to a substantial lessening of competition. For that, parties can seek confidential advice under section 55A of the Competition Act 2004.

When confidential advice is worth it

Confidential advice is available only if three conditions are met: the merger has not been completed but there is a good faith intention to proceed, the deal is not yet public, and it raises a genuine issue about competitive assessment in Singapore. CCS expects to give advice within 14 working days of receiving all the required information, but it does not consult third parties and the advice is not binding.

The CCS merger guidelines 2026 add a safeguard: if CCS decides the conditions are not met, it will securely destroy the confidential information rather than return it. For sensitive pre-announcement deals in concentrated markets, confidential advice can tell the board whether a notification condition belongs in the term sheet before anything is public.

Phase 1: streamlined, standard or extended

The Phase 1 clock starts on the working day after CCS receives a satisfactory application. CCS will first check that Form M1 is complete, that supporting documents and the fee are included and that the application is substantially in the prescribed form. An incomplete filing simply does not start the clock.

Under the CCS merger guidelines 2026, a merger that clearly does not raise competition concerns receives a streamlined assessment completed within 25 working days. CCS expects most mergers to fall into this track. Others receive the standard 30 working day review. In limited circumstances, such as where CCS needs more information or the case involves a novel theory of harm, Phase 1 can be extended by up to 20 working days to a maximum of 50.

CCS can also stop the clock, for example if parties miss deadlines for information requests, if commitments are under consideration, or if confidentiality claims in Form M1 are excessive. Third parties are invited to comment once a summary of the application is published, and delays in essential third-party information are one of the exceptional circumstances in which CCS may discuss whether 50 working days is enough.

Practical point: over-claiming confidentiality now costs time

Parties now submit only a confidential Form M1, with confidential material in square brackets and a written explanation of why it is confidential. If CCS considers the claims excessive or unreasonable, it may stop the clock until they are fixed. Mark only what is genuinely sensitive, such as non-public financials and customer-specific data, and prepare the justifications in advance.

The Phase 1 Issues Letter and the commitments decision

The most significant new tool in the CCS merger guidelines 2026 is the Phase 1 Issues Letter. If CCS has reasonable grounds to suspect that the merger may infringe section 54 at the end of Phase 1, it sends a letter summarising its key competition concerns and indicating that it is unlikely to clear the merger if they remain unaddressed. The letter sets a deadline either to offer a final commitments proposal or to submit Form M2 for Phase 2.

Offering commitments is voluntary. If CCS accepts a final proposal in principle for market testing, a separate 50 working day timeline begins for evaluating it, which CCS can extend by up to 20 working days. If CCS does not accept the proposal, it will require Form M2 by a set date. If parties do neither, CCS will generally open an investigation.

Phase 2 under the revised guidelines

Phase 2 now has a 100 working day target. The clock starts only when CCS has notified the parties and received both a complete Form M2 and a response to its Phase 2 information request. CCS will not extend Phase 2 to evaluate commitments except in exceptional circumstances, so it encourages parties to offer remedies as early as possible. Towards the end of Phase 2, if CCS's preliminary view is that the merger is likely to lessen competition substantially, it issues a Statement of Decision (Provisional).

The practical result is that remedies thinking moves forward. Before May 2026 there was no formal Phase 1 issues mechanism; under the CCS merger guidelines 2026, the natural point to table them is the Issues Letter deadline at the end of Phase 1, and the absence of routine Phase 2 extensions reinforces that. A buyer in an overlapping market should analyse possible divestments or behavioural commitments before signing, so it can respond to an Issues Letter within the deadline rather than starting from scratch.

Building the CCS merger guidelines 2026 into a deal timetable

Working days exclude weekends and Singapore public holidays, so a rough conversion is five working days to a calendar week. On that basis, 25 working days is about five weeks, 50 about ten weeks and 100 about twenty weeks, before allowing for clock stops, completeness checks and public holidays.

  1. Screen the deal early. Map overlaps and vertical links in Singapore and estimate shares against CCS's indicative thresholds. Decide whether to notify, seek confidential advice or proceed without filing.
  2. Draft the conditions precedent. If notifying, make CCS clearance a condition and allocate responsibility for filing, cooperation and remedies. Consider whether the buyer must offer commitments and where the limit lies.
  3. Set the long-stop date. For a streamlined case, allow for pre-notification, the completeness check and 25 working days. For a deal with overlaps, plan for an extended Phase 1, an Issues Letter, a commitments evaluation of up to 70 working days and possibly a 100 working day Phase 2.
  4. Prepare a complete Form M1. Use pre-notification discussions to agree what information is needed, mark confidentiality carefully and assemble internal documents and market data in advance.
  5. Plan the remedies response. Prepare a remedies analysis before filing in any deal with material overlaps, so the board can act within the Issues Letter deadline.
  6. Coordinate with other regulators. Align the Singapore filing with other merger control and foreign investment filings, and with the Take-over Code timetable for public deals.

Long-stop dates in sale agreements negotiated before May 2026 may be more generous than a simple Singapore filing now needs, but they may be too short for a complex case if they did not anticipate the Issues Letter step. Our M&A support team can review conditions and long-stop drafting against the new timelines.

Illustrative scenario: a regional buyer with a local overlap

This scenario is illustrative; the parties are hypothetical. A regional industrial gases supplier agrees to buy a Singapore distributor. In most product lines the overlap is small, but in one specialty gas the combined share would be close to 40%. The parties seek a pre-notification meeting with a draft Form M1 and a draft sale agreement.

Expecting the standard track rather than the streamlined one, the buyer sets a long-stop date that allows for an extended Phase 1, an Issues Letter and a commitments evaluation, with an option to extend if Phase 2 is needed. Before filing, it prepares a remedies analysis identifying a customer contract portfolio it could divest in the specialty gas.

CCS issues a Phase 1 Issues Letter on the specialty gas. Because the analysis is ready, the buyer submits a final commitments proposal within the deadline. CCS market-tests it and clears the deal in Phase 1 with commitments, avoiding a Phase 2 review. The rest of the business, where there were no concerns, was never at risk.

Risks and common mistakes

Assuming the streamlined track applies

CCS decides which track applies. A deal with any meaningful overlap or vertical link should not be timed on the 25 working day assumption. Build in the standard 30 working days at least, and more where markets are concentrated or poorly defined.

Treat the streamlined track as a possible benefit rather than a planning baseline.

Filing an incomplete Form M1

The Phase 1 clock does not start until CCS is satisfied the application is complete. Missing information, the wrong fee or inadequate confidentiality justifications all delay the start date. Use pre-notification discussions with a draft form to flush out gaps.

Applicants that respond late to information requests also risk CCS stopping the clock.

Leaving remedies until Phase 2

CCS will not extend Phase 2 to evaluate commitments except in exceptional circumstances, and the Issues Letter sets a deadline at the end of Phase 1. A buyer that has not considered remedies before filing may be forced into Phase 2 by default.

Agree internally, and in the sale agreement, how far the buyer will go on divestments or behavioural undertakings.

Forgetting completed deals and interim measures

The regime is voluntary, but CCS can investigate completed mergers and may impose interim measures to prevent action that would prejudice its investigation or remedies, such as integration steps. Closing without notifying in a concentrated market transfers that risk to the buyer after completion.

Consider confidential advice or notification where the indicative thresholds are approached.

Cross-border deals and what to do next

Global transactions often need filings in several jurisdictions, and Singapore's timetable must fit around them. CCS regularly reviews multinational deals; in 2026 alone it has published consultations on transactions involving semiconductors, fuels and steel. For deals subject to the Singapore Code on Take-overs and Mergers, Appendix 3 to the Code contains guidance on how CCS merger procedures interact with the offer timetable; see our note on the 2026 Take-over Code revisions.

TRW & Co coordinates merger filings across its offices in Bangladesh, the UK, the UAE, China and Europe, working with local counsel and with Singapore-qualified counsel where required. Before signing, a deal team should screen Singapore overlaps, decide whether to file or seek confidential advice, set conditions and long-stop dates against the CCS merger guidelines 2026, and prepare a remedies fallback. Our overview of competition law in Singapore and our private equity transactions page cover related issues. To plan a Singapore filing, contact TRW & Co.

Frequently asked questions

01Is merger notification mandatory in Singapore after the 2026 changes?

No. Singapore's merger regime remains voluntary. The 2026 changes are procedural and do not create a filing obligation. Parties self-assess whether their deal may substantially lessen competition and decide whether to notify. CCS can still investigate completed or anticipated mergers that were not notified and can impose interim measures, so the commercial question is who bears the risk of a post-closing review.

02How long does a CCS merger review take now?

Under the guidelines effective 1 May 2026, a streamlined Phase 1 is completed within 25 working days and a standard Phase 1 within 30 working days, extendable in limited cases to 50. If a commitments proposal is market-tested, a separate 50 working day evaluation period applies, extendable by up to 20. Phase 2 has a 100 working day target. The clock starts only when CCS accepts a complete application, and CCS can stop it in some circumstances.

03What is a Phase 1 Issues Letter?

It is a letter CCS sends at the end of Phase 1 if it has reasonable grounds to suspect that the merger may infringe section 54 of the Competition Act. It summarises the key competition concerns, says CCS is unlikely to clear the merger if they remain unaddressed, and sets a deadline either to submit a final commitments proposal or to file Form M2 for a Phase 2 review. Parties also have an opportunity to respond to it.

04Do we still need a non-confidential version of Form M1?

Not as a matter of course. The revised guidelines require a confidential version of Form M1 with confidential information in square brackets and a written explanation of why it is confidential. CCS will ask for a non-confidential version only if it considers one necessary. Excessive or unreasonable confidentiality claims can lead CCS to stop the clock until they are corrected.

05Can we get CCS's view before our deal is announced?

Yes, through confidential advice, if three conditions are met: the merger is not completed but there is a good faith intention to proceed, it is not in the public domain, and it raises a genuine issue about competitive assessment in Singapore. CCS expects to respond within 14 working days of receiving full information. The advice is not binding and does not take third-party views into account.

06Did the 2026 changes alter the merger thresholds or substantive test?

No. The revisions concern the Guidelines on Merger Procedures, with consequential changes to other guidelines. The test remains whether the merger has resulted, or may be expected to result, in a substantial lessening of competition. CCS's website continues to state that concerns are unlikely unless the merged entity has 40% or more of a market, or 20% to 40% where the three largest firms hold 70% or more.

Sources and official materials

  1. CCS media release, 27 March 2026: Revisions to CCS's Merger Procedure Guidelines — Streamlined track, reduced burden and earlier clarity; effective 1 May 2026
  2. CCS: Competition Act and Guidelines — Current CCS Guidelines on Merger Procedures
  3. CCS: Mergers and Acquisitions — Indicative thresholds and the voluntary regime
  4. CCS: Discuss a merger with CCS — How to request pre-notification discussions
  5. CCS: Merger assessment process — Overview of Phase 1, Phase 2 and decisions
  6. CCS media release, 27 October 2025: consultation on two key guidelines — Consultation on merger procedure changes
  7. Competition Act 2004 — Sections 54, 55A, 57, 58 and 58A

General information only, current as at 20 October 2026. It is not legal advice and does not create a lawyer–client relationship. Singapore law and regulatory practice change; check current official sources and take advice on the facts of your matter.

TRW on LinkedIn & Facebook

From the firm,
this week.

Conference notes, transactions in the news and the people we work with — follow TRW & Co for the full feed.

Call the Singapore desk+880 1779 127165 WhatsApp · message usMessage our team